$8.70+0.33 (+3.88%)
Red Cat Holdings, Inc., together with its subsidiaries, provides drone and robotic solutions for defense, national security, and commercial applications in the United States.
Red Cat Holdings, Inc. in the Industrials sector is trading at $8.70 with a market capitalization of $1.3B. Wall Street consensus targets $16.75 (8 analysts), implying a +92.6% move over the next 12 months. The stock is currently 54% below its 52-week high of $18.78, remaining 20.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.47M↓ | $26.23M↑ | $9.65M↑ | $3.22M↑ | $1.63M |
| Gross Profit | $1.97M↑ | $1.11M↑ | $637,502↑ | $375,054↑ | -$850,000 |
| Operating Income | -$27.30M↓ | -$23.94M↓ | -$17.53M↓ | -$12.65M↓ | -$12.48M |
| Net Income | -$26.55M↓ | -$19.66M↓ | -$16.02M↓ | -$13.28M↑ | -$23.12M |
Red Cat Holdings, Inc., together with its subsidiaries, provides drone and robotic solutions for defense, national security, and commercial applications in the United States. The company designs and manufactures small and tactical unmanned aircraft s...

UMAC stock has exploded higher while its closest drone rivals have actually lost ground, putting investors at a crossroads that could define their returns for the rest of the year.

Ondas has lifted its 2026 revenue outlook as Q2 sales and backlog have surged, putting backlog conversion and margin progress at the center of execution.

ONDS' 18.2% pullback comes as revenues, backlog and orders surge, but widening losses, cash burn and M&A integration risks still cloud the value case.

ONDS pairs explosive 2026 revenue growth and a $757 million backlog with widening losses, cash burn and integration risks that test its path to profit.

Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks.